Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Legubicin in recurrent ovarian cancer and relapsed/refractory choriocarcinoma
CTR20252681Phase 2Active
- Sponsor
- Shanghai Qinheli Biotechnology
- Start
- Jul 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lecubicin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), choriocarcinoma, sponsored by Shanghai Qinheli Biotechnology. Started Jul 2025; status: active.
02
Drugs
lecubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)choriocarcinoma
Beyond the preview
Go deeper on CTR20252681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252681.